Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease.

[1]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[2]  K. Gardiner,et al.  Immunosuppression in patients with Crohn's disease and neoplasia: an ongoing clinical dilemma. , 2012, Diseases of the colon and rectum.

[3]  A. Ananthakrishnan,et al.  Effects of cancer treatment on inflammatory bowel disease remission and reactivation. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  Christopher F. Martin,et al.  Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. , 2012, Gastroenterology.

[5]  H. Sokol,et al.  Factors affecting outcomes in Crohn's disease over 15 years , 2012, Gut.

[6]  C. Cordon-Cardo,et al.  A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2‐T4aN0‐N2M0 bladder cancer , 2012, Cancer.

[7]  L. Beaugerie.  Inflammatory bowel disease therapies and cancer risk: where are we and where are we going? , 2011, Gut.

[8]  J. Hugot,et al.  Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. , 2011, Gastroenterology.

[9]  Paul Emery,et al.  Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis , 2011, Annals of the rheumatic diseases.

[10]  G. Calais,et al.  Randomized phase III trial (GORTEC 98-03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with a palliative intent. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  M. Neovius,et al.  Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. , 2011, Arthritis and rheumatism.

[12]  Philippe Seksik,et al.  Epidemiology and natural history of inflammatory bowel diseases. , 2011, Gastroenterology.

[13]  K. Hemminki,et al.  Survival in cancer patients hospitalized for inflammatory bowel disease in Sweden , 2011, Inflammatory bowel diseases.

[14]  I. Lavery,et al.  Effects of Chronic Immunosuppression on Long-term Oncologic Outcomes for Colorectal Cancer Patients Undergoing Surgery , 2011, Annals of surgery.

[15]  J. Larkin,et al.  A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma , 2010, British Journal of Cancer.

[16]  C. Loprinzi,et al.  A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). , 2010, Lung cancer.

[17]  J. Kempen,et al.  Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study , 2009, BMJ : British Medical Journal.

[18]  D. M. van der Heijde,et al.  Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research , 2008, Annals of the rheumatic diseases.

[19]  A. Tookman,et al.  Fatigue in patients with advanced cancer: a pilot study of an intervention with infliximab , 2008, Supportive Care in Cancer.

[20]  T. Lash,et al.  Survival in Danish patients with breast cancer and inflammatory bowel disease: A nationwide cohort study , 2008, Inflammatory bowel diseases.

[21]  C. Harris,et al.  Inflammation and cancer: An ancient link with novel potentials , 2007, International journal of cancer.

[22]  M. Gore,et al.  Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Ulrich,et al.  Azathioprine, UV light, and skin cancer in organ transplant patients--do we have an answer? , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  L. Beaugerie,et al.  Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery , 2005, Gut.

[25]  P. Beauparlant,et al.  The incidence of cancer associated with the treatment of rheumatoid arthritis. , 1999, Seminars in arthritis and rheumatism.

[26]  濱口 貴彦.  TNF inhibitor suppresses bone metastasis in a breast cancer cell line , 2012 .

[27]  J. Stockman.  Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study , 2011 .

[28]  K. Hemminki,et al.  Cancer risks in Crohn disease patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  P. Malfertheiner,et al.  A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. , 2008, The journal of supportive oncology.